secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001193125-25-119402
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma reports Q3 FY2025 net loss of $9.4M; cash $103.6M; BB-301 low-dose cohort completed
--------------------------------------------------------------------------------

- Net loss of $9.4M ($0.24/share) vs $4.3M ($0.23/share) in prior year; expenses rose to $10.2M on higher R&D and G&A.
- Cash and cash equivalents $103.6M as of March 31, 2025, up from $50.9M at June 30, 2024.
- BB-301: sixth and final subject in Cohort 1 (low dose) treated safely in April 2025; enrollment at higher dose expected later this year.
- Additional clinical study updates for Cohort 1 subjects planned for Q4 calendar 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525119402/0001193125-25-119402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525119402/d52557d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-119402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer